Invesco Ltd. Has $3.90 Million Stock Holdings in Certara, Inc. $CERT

Invesco Ltd. lifted its position in shares of Certara, Inc. (NASDAQ:CERT) by 0.3% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 394,037 shares of the company’s stock after buying an additional 1,285 shares during the quarter. Invesco Ltd. owned about 0.24% of Certara worth $3,901,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of CERT. Versant Capital Management Inc grew its stake in shares of Certara by 218.8% in the first quarter. Versant Capital Management Inc now owns 2,719 shares of the company’s stock valued at $27,000 after acquiring an additional 1,866 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in Certara by 48.4% in the 4th quarter. Wells Fargo & Company MN now owns 3,208 shares of the company’s stock valued at $34,000 after purchasing an additional 1,047 shares during the period. Associated Banc Corp bought a new stake in Certara in the 1st quarter valued at about $101,000. Portside Wealth Group LLC acquired a new position in shares of Certara during the 1st quarter worth approximately $104,000. Finally, Janney Montgomery Scott LLC bought a new position in shares of Certara during the first quarter worth approximately $120,000. Institutional investors own 73.96% of the company’s stock.

Certara Stock Performance

Shares of Certara stock opened at $10.87 on Friday. The company’s 50 day moving average price is $10.82 and its two-hundred day moving average price is $11.50. The firm has a market capitalization of $1.75 billion, a P/E ratio of 217.44 and a beta of 1.42. Certara, Inc. has a fifty-two week low of $8.64 and a fifty-two week high of $15.69. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.16 and a quick ratio of 2.16.

Certara (NASDAQ:CERT) last announced its quarterly earnings results on Wednesday, August 6th. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). The firm had revenue of $104.57 million during the quarter, compared to the consensus estimate of $104.14 million. Certara had a net margin of 1.97% and a return on equity of 5.11%. The firm’s revenue was up 12.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.07 earnings per share. On average, equities analysts forecast that Certara, Inc. will post 0.28 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on CERT. KeyCorp cut their price target on Certara from $18.00 to $15.00 and set an “overweight” rating for the company in a research note on Monday, July 14th. JMP Securities reiterated a “market perform” rating on shares of Certara in a research report on Tuesday, May 6th. Morgan Stanley started coverage on Certara in a report on Thursday, July 3rd. They set an “equal weight” rating and a $16.00 target price on the stock. Barclays raised Certara from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $11.00 to $14.00 in a research note on Thursday, May 8th. Finally, UBS Group cut their price objective on shares of Certara from $17.50 to $15.00 and set a “buy” rating for the company in a research report on Thursday, August 7th. Five investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $15.14.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.